Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 535Squamous Cell Carcinoma of Head and Neck 274Head and Neck Neoplasms 253Lung Neoplasms 239Uterine Cervical Neoplasms 178Stomach Neoplasms 168Esophageal Neoplasms 160Nasopharyngeal Carcinoma 123Urinary Bladder Neoplasms 116Esophageal Squamous Cell Carcinoma 115Neoplasms 114Small Cell Lung Carcinoma 104Breast Neoplasms 92Neoplasm Metastasis 91Ovarian Neoplasms 89Cholangiocarcinoma 77Carcinoma, Squamous Cell 76Pancreatic Neoplasms 73Biliary Tract Neoplasms 70Mesothelioma, Malignant 57Oropharyngeal Neoplasms 56Carcinoma 56Adenocarcinoma Of Esophagus 52Recurrence 47Parkinson Disease 4, Autosomal Dominant Lewy Body 47Carcinoma, Ovarian Epithelial 45Nasopharyngeal Neoplasms 41Lymphoma 41Adenocarcinoma of Lung 41Triple Negative Breast Neoplasms 38

Interventions

Trastuzumab 1Paclitaxel 1MM-111 1Lapatinib 1Docetaxel 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × HER-2 Gene Amplification × Cisplatin × Clear all
NCT01304784 2015-12-16

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

Merrimack Pharmaceuticals

Phase 1 Completed
100 enrolled

HER-2 Gene Amplification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡